Literature DB >> 12925969

Risk modification by CYP1A1 and GSTM1 polymorphisms in the association of environmental tobacco smoke and lung cancer: a case-control study in Japanese nonsmoking women.

Chikako Kiyohara1, Kenji Wakai, Haruo Mikami, Koichi Sido, Masahiko Ando, Yoshiyuki Ohno.   

Abstract

Genetic backgrounds may modify the association of environmental tobacco smoke (ETS) with lung cancer risk. Polymorphisms of both the activating and detoxifying enzymes, cytochrome P4501A1 (CYP1A1) and glutathione-S-transferase M1 (GSTM1), may be important as genetic factors. We conducted a multicenter case-control study in Japanese nonsmoking women. Cases were women aged 30-89 years and newly diagnosed as having lung cancer from November 1997 to March 2001 in 4 study areas. We also recruited age-matched (5-year strata) and hospital-matched nonsmoking controls. A total of 158 cases and 259 hospital controls supplied blood for genotyping. Detailed information on ETS exposure from husbands and that in other situations and on potential confounders was collected by interview. Odds ratios (ORs) were estimated by using conditional logistic models. We found no increase in the risk of lung cancer for CYP1A1 Msp I genotypes. For the GSTM1 null genotype vs. nonnull genotype, the OR was 1.37 [95% confidence interval (CI) 0.90-2.09], which indicated a somewhat increased risk for the GSTM1 null genotype. A gene-environment interaction was suggested, with combined GSTM1 null genotype and high-dose ETS exposure (>/=40 pack-years by husbands) conferring significantly higher risk (OR = 2.27, 95% CI 1.13-4.57) compared to the GSTM1 nonnull genotype and low-dose ETS exposure (<40 pack-years). Our results do not support a major role of Msp I polymorphism of the CYP1A1 gene as a risk factor for lung cancer among nonsmoking women. In contrast, the GSTM1 null genotype posed an increased, although not significant, risk among them. Additional studies are warranted to confirm the ETS-GSTM1 polymorphism interaction suggested in our present study. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12925969     DOI: 10.1002/ijc.11355

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

1.  Assessment of cumulative evidence for the association between glutathione S-transferase polymorphisms and lung cancer: application of the Venice interim guidelines.

Authors:  Scott M Langevin; John P A Ioannidis; Paolo Vineis; Emanuela Taioli
Journal:  Pharmacogenet Genomics       Date:  2010-10       Impact factor: 2.089

2.  Evaluating the evidence for the relationship between passive smoking and lung cancer.

Authors:  Claire H Kim; Lina Mu; Ming Wu; Jin-Kou Zhao; Zuo-Feng Zhang
Journal:  Int J Cancer       Date:  2014-04-07       Impact factor: 7.396

3.  GSTM1 polymorphism and lung cancer risk among East Asian populations: a meta-analysis.

Authors:  Yan Zhao; Junjie Zeng; Yanxi Zhang; Su Lu; Erjiang Zhao; Ziming Huang; Weiquan Lu
Journal:  Tumour Biol       Date:  2014-04-01

4.  Glutathione S-transferase M1 and T1 null genotype frequency distribution among four tribal populations of western India.

Authors:  Prem Chandra Suthar; Pulakes Purkait; Kiran Uttaravalli; B N Sarkar; Rakshit Ameta; Mithun Sikdar
Journal:  J Genet       Date:  2018-03       Impact factor: 1.166

5.  GSTM1 and GSTT1 polymorphism and susceptibility to esophageal cancer in high- and low-risk regions of India.

Authors:  Anita Sharma; Bhudev Chander Das; Ashok Sehgal; Ravi Mehrotra; Premashish Kar; Sarita Sardana; Rup Phukan; Jagdish Mahanta; Joydeep Purkayastha; Sunita Saxena; Sujala Kapur; Indranil Chatterjee; Joginder Kumar Sharma
Journal:  Tumour Biol       Date:  2013-06-08

6.  Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study.

Authors:  P Vineis; L Airoldi; F Veglia; L Olgiati; R Pastorelli; H Autrup; A Dunning; S Garte; E Gormally; P Hainaut; C Malaveille; G Matullo; M Peluso; K Overvad; A Tjonneland; F Clavel-Chapelon; H Boeing; V Krogh; D Palli; S Panico; R Tumino; B Bueno-De-Mesquita; P Peeters; G Berglund; G Hallmans; R Saracci; E Riboli
Journal:  BMJ       Date:  2005-01-28

Review 7.  Lung cancer in never smokers.

Authors:  Ping Yang
Journal:  Semin Respir Crit Care Med       Date:  2011-04-15       Impact factor: 3.119

Review 8.  Lung cancer in never smokers: molecular profiles and therapeutic implications.

Authors:  Charles M Rudin; Erika Avila-Tang; Curtis C Harris; James G Herman; Fred R Hirsch; William Pao; Ann G Schwartz; Kirsi H Vahakangas; Jonathan M Samet
Journal:  Clin Cancer Res       Date:  2009-09-15       Impact factor: 12.531

9.  Polymorphisms of Metabolizing Enzymes and Susceptibility to Ethmoid Intestinal-type Adenocarcinoma in Professionally Exposed Patients.

Authors:  Elisa Pastore; Federica Perrone; Marta Orsenigo; Luigi Mariani; Clara Millefanti; Stefano Riccio; Sarah Colombo; Giulio Cantù; Marco A Pierotti; Silvana Pilotti
Journal:  Transl Oncol       Date:  2009-05       Impact factor: 4.243

Review 10.  CYP1A1 MspI and exon7 gene polymorphisms and lung cancer risk: an updated meta-analysis and review.

Authors:  Ping Zhan; Qin Wang; Qian Qian; Shu-Zhen Wei; Li-Ke Yu
Journal:  J Exp Clin Cancer Res       Date:  2011-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.